Engineered virus takes on deadly brain cancer
NCT ID NCT02062827
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a single dose of M032, a genetically modified herpes simplex virus that produces IL-12, in 29 patients with recurrent or progressive brain tumors (glioblastoma, anaplastic astrocytoma, or gliosarcoma). The virus is infused directly into the tumor area via catheters. The main goal is to find the safest dose and see if the body tolerates it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- M032 (a genetically modified herpes simplex virus that delivers IL-12)
- What this could lead to
- If this works, it could point toward a new treatment option for aggressive brain tumors that have come back after standard therapy.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, not effectiveness. The virus may not work against the tumor or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a parasite drug fight childhood brain tumors?
- Can mapping the Blood-Brain barrier in brain tumors unlock new clues?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack
- AI reads brain scans to predict tumor survival before surgery
- Can a drug make radiation work better against aggressive brain tumors?